Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035753) 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2017/035753 International Application No.: PCT/CN2015/088643
Publication Date: 09.03.2017 International Filing Date: 31.08.2015
IPC:
C07D 471/04 (2006.01) ,C07D 495/04 (2006.01) ,C07D 403/04 (2006.01) ,C07D 401/04 (2006.01) ,C07D 405/04 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/437 (2006.01) ,A61K 31/403 (2006.01) ,A61K 31/506 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
495
Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
无锡双良生物科技有限公司 WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. [CN/CN]; 中国江苏省 江阴市东盛西路6号A5楼 Building A5, 6 Dongsheng West Road Jiangyin, Jiangsu 214437, CN
Inventors:
吴家权 WU, Jiaquan; CN
张海军 ZHANG, Haijun; US
曹焕岩 CAO, Huanyan; CN
金深霜 JIN, Shenshuang; CN
张帅 ZHANG, Shuai; CN
陆政华 LU, Zhenghua; CN
董健 DONG, Jian; CN
王赪晨 WANG, Chengchen; CN
谈秋 TAN, Qiu; CN
Agent:
北京林达刘知识产权代理事务所(普通合伙) LINDA LIU & PARTNERS; 中国北京市 东城区北三环东路36号北京环球贸易中心C座16层 F16 Tower C, Beijing Global Trade Center, 36 North Third Ring East Road, Beijing 100013, CN
Priority Data:
Title (EN) 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
(FR) 2-ARYLAMINO PYRIDINE, DÉRIVÉ DE PYRIDINE OU DE TRIAZINE, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION
(ZH) 2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途
Abstract:
(EN) The invention relates to a 2-arylamino pyridine, a pyridine or triazine derivative, a preparation method and a use thereof. The 2-arylamino pyridine, or the pyridine or triazine derivative can act on certain mutated epidermal growth factor receptors (EGFR) such as an L858R activating mutant, a delE746_A750 mutant, an Exonl9 deletion activating mutant, and a T790M drug-resistant mutant, so as to treat and prevent a disease and a condition. The 2-arylamino pyridine or the pyridine or triazine derivative can find applications in treating or prevention of cancers. The invention also relates to a pharmaceutical composition comprising the 2-arylamino pyridine or the pyridine or triazine derivative and applicable to prepare an intermediate of the 2-arylamino pyridine or the pyridine or triazine derivative, and relates to a method employing the 2-arylamino pyridine or the pyridine or triazine derivative to treat various types of EGFR-mediated diseases.
(FR) L'invention concerne une 2-arylamino pyridine, un dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation. La 2-arylamino pyridine, le dérivé de pyridine ou de triazine peuvent agir sur certains récepteurs du facteur de croissance épidermique (EGFR) mutés, par exemple un mutant d'activation L858R, un mutant delE746_a750, un mutant d'activation de délétion d'Exonl9 et un mutant pharmacorésistant T790M, de manière à traiter et prévenir une maladie et une pathologie. La 2-arylamino pyridine ou le dérivé de pyridine ou de triazine peuvent trouver des applications dans le traitement ou la prévention de cancers. L'invention concerne également une composition pharmaceutique comprenant la 2-arylamino pyridine ou le dérivé de pyridine ou de triazine, et applicable pour préparer un intermédiaire de la 2-arylamino pyridine ou du dérivé de pyridine ou de triazine, et concerne un procédé utilisant la 2-arylamino pyridine ou le dérivé de pyridine ou de triazine pour traiter divers types de maladies conditionnées par l'EGFR.
(ZH) 本发明涉及2-芳胺基吡啶、嘧啶或三嗪衍生物及其制备方法和用途。所述2-芳胺基吡啶、嘧啶或三嗪衍生物可以作用于某些突变形式的表皮生长因子受体,例如L858R激活突变体、delE746_A750突变体、Exonl9缺失激活突变体和T790M耐药突变体,从而用于疾病和病况的治疗和预防。所述2-芳胺基吡啶、嘧啶或三嗪衍生物可用于癌症的治疗和预防。本发明还涉及包含2-芳胺基吡啶、嘧啶或三嗪衍生物的药物组合物,可用于制备2-芳胺基吡啶、嘧啶或三嗪衍生物的中间体,以及利用2-芳胺基吡啶、嘧啶或三嗪衍生物治疗由各种不同形式EGFR所介导的疾病的方法。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)